Sign In
NASDAQ:BIIB
Biogen Inc. Stock Earnings Reports
$139.44
-0.540 (-0.386%)
At Close: Mar 14, 2025
Biogen. Earnings Calls
Q4 2024
Beat
$3.44 (0.292%)
| Release date | Feb 12, 2025 |
| EPS estimate | $3.43 |
| EPS actual | $3.44 |
| EPS Surprise | 0.292% |
| Revenue estimate | 2.408B |
| Revenue actual | 2.455B |
| Revenue Surprise | 1.93% |
Q3 2024
Beat
$4.08 (8.22%)
| Release date | Oct 30, 2024 |
| EPS estimate | $3.77 |
| EPS actual | $4.08 |
| EPS Surprise | 8.22% |
| Revenue estimate | 2.435B |
| Revenue actual | 2.466B |
| Revenue Surprise | 1.29% |
Q2 2024
Beat
$5.28 (29.73%)
| Release date | Aug 01, 2024 |
| EPS estimate | $4.07 |
| EPS actual | $5.28 |
| EPS Surprise | 29.73% |
| Revenue estimate | 2.392B |
| Revenue actual | 2.353B |
| Revenue Surprise | -1.65% |
Q1 2024
Beat
$3.67 (5.76%)
| Release date | Apr 24, 2024 |
| EPS estimate | $3.47 |
| EPS actual | $3.67 |
| EPS Surprise | 5.76% |
| Revenue estimate | 2.309B |
| Revenue actual | 2.2B |
| Revenue Surprise | -4.71% |
Last 4 Quarters for Biogen.
Below you can see how BIIB performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | Apr 24, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $201.99 |
| EPS estimate | $3.47 |
| EPS actual | $3.67 |
| EPS surprise | 5.76% |
| Date | Price |
|---|---|
| Apr 18, 2024 | $190.52 |
| Apr 19, 2024 | $194.38 |
| Apr 22, 2024 | $194.11 |
| Apr 23, 2024 | $193.18 |
| Apr 24, 2024 | $201.99 |
| Apr 25, 2024 | $202.46 |
| Apr 26, 2024 | $208.90 |
| Apr 29, 2024 | $215.50 |
| Apr 30, 2024 | $214.82 |
| 4 days before | 6.02% |
| 4 days after | 6.35% |
| On release day | 0.233% |
| Change in period | 12.75% |
Q2 2024
Beat
| Release date | Aug 01, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $210.70 |
| EPS estimate | $4.07 |
| EPS actual | $5.28 |
| EPS surprise | 29.73% |
| Date | Price |
|---|---|
| Jul 26, 2024 | $211.17 |
| Jul 29, 2024 | $214.43 |
| Jul 30, 2024 | $211.89 |
| Jul 31, 2024 | $213.20 |
| Aug 01, 2024 | $210.70 |
| Aug 02, 2024 | $205.66 |
| Aug 05, 2024 | $198.39 |
| Aug 06, 2024 | $200.13 |
| Aug 07, 2024 | $199.78 |
| 4 days before | -0.223% |
| 4 days after | -5.18% |
| On release day | -2.39% |
| Change in period | -5.39% |
Q3 2024
Beat
| Release date | Oct 30, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $181.18 |
| EPS estimate | $3.77 |
| EPS actual | $4.08 |
| EPS surprise | 8.22% |
| Date | Price |
|---|---|
| Oct 24, 2024 | $183.86 |
| Oct 25, 2024 | $181.69 |
| Oct 28, 2024 | $185.01 |
| Oct 29, 2024 | $183.47 |
| Oct 30, 2024 | $181.18 |
| Oct 31, 2024 | $174.00 |
| Nov 01, 2024 | $173.79 |
| Nov 04, 2024 | $173.52 |
| Nov 05, 2024 | $176.93 |
| 4 days before | -1.46% |
| 4 days after | -2.35% |
| On release day | -3.96% |
| Change in period | -3.77% |
Q4 2024
Beat
| Release date | Feb 12, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $133.43 |
| EPS estimate | $3.43 |
| EPS actual | $3.44 |
| EPS surprise | 0.292% |
| Date | Price |
|---|---|
| Feb 06, 2025 | $142.37 |
| Feb 07, 2025 | $141.00 |
| Feb 10, 2025 | $142.54 |
| Feb 11, 2025 | $139.39 |
| Feb 12, 2025 | $133.43 |
| Feb 13, 2025 | $138.45 |
| Feb 14, 2025 | $137.33 |
| Feb 18, 2025 | $136.53 |
| Feb 19, 2025 | $136.68 |
| 4 days before | -6.28% |
| 4 days after | 2.44% |
| On release day | 3.76% |
| Change in period | -4.00% |
Biogen. Earnings Call Transcript Summary of Q4 2024
Company Overview
The company is launching innovative products targeting Alzheimer's, Friedreich’s ataxia, depression, and ALS, marking significant advances in disease-modifying treatments.
Financial Highlights
- Q4 2024 total revenue of $2.5 billion, reflecting 3% growth year-over-year.
- Full year 2024 revenue decreased by 2% to $9.7 billion.
- Non-GAAP diluted EPS increased by 17% in Q4 to $3.44, and for the full year, it rose by 12% to $16.47.
- Free cash flow stood at $722 million for Q4 and $2.7 billion for the full year, up from $1.3 billion in 2023.
Product Performance
- Multiple sclerosis revenue decreased 8%, attributed to competition, including generics and biosimilar entrants.
- Notable growth in rare disease therapies, particularly:
- SKYCLARYS: Revenue increased by 83% to $102 million in Q4, with continued patient additions.
- SPINRAZA: Revenue up 2% year-over-year.
- LEQEMBI: Generated $87 million in Q4, reflecting a 30% increase quarter-over-quarter, driven by strong demand.
- Generic and biosimilar pressures are impacting traditional MS revenues, necessitating the success of new product launches to offset losses.
Research and Development Insights
- Biogen has refined its R&D pipeline, focusing on high-conviction projects likely to yield significant market impact. Key therapeutic areas include Alzheimer’s disease and immunology.
- The AHEAD 3-45 trial aims at preventing Alzheimer’s disease, with early results expected to be promising.
- New formulations of LEQEMBI and blood-based diagnostics could facilitate easier access to treatment, potentially driving revenues upward.
Business Strategy
- The company emphasizes a disciplined approach to business development, looking to acquire assets that complement its existing portfolio while focusing on R&D innovations.
- Management aims for sustainable revenue growth through internal capabilities, judicious acquisitions, and expansion into international markets.
Future Outlook
- 2025 guidance expects total revenue to decline in mid-single digits, largely due to continued MS revenue erosion, albeit countered by anticipated growth from new product launches.
- Expected combined R&D and SG&A expenses for 2025 are projected to be approximately $3.9 billion, incorporating significant cost transformation initiatives (Fit for Growth).
Transitioning Leadership
- Mike McDonnell announced retirement, and Robin Kramer will assume the CFO role — management transition expected to maintain continuity amid strategic growth.
Investor Takeaway
Investors should monitor Biogen’s ability to successfully launch and expand its new product lines, navigate competitive pressures in the MS market, and capitalize on its revitalized R&D pipeline. Additionally, understanding the impact of emerging therapies and market conditions will be vital for assessing Biogen’s growth trajectory moving forward.
Biogen. Earnings History
Earnings Calendar
FAQ
When is the earnings report for BIIB?
Biogen Inc. (BIIB) has scheduled its earnings report for Apr 23, 2025 before the markets open.
What is the BIIB price-to-earnings (P/E) ratio?
BIIB P/E ratio as of Mar 14, 2025 (TTM) is 12.45.
What is the BIIB EPS forecast?
The forecasted EPS (Earnings Per Share) for Biogen Inc. (BIIB) for the first fiscal quarter 2025 is $3.59.
What are Biogen Inc.'s retained earnings?
On its balance sheet, Biogen Inc. reported retained earnings of $2.45 billion for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
